Form 4: Plus Therapeutics Director Acquires Stock Options

Robert P. Lenk, a director of Plus Therapeutics, Inc., acquired stock options exercisable for 3,650 shares of common stock on September 11, 2024.

Summary

• On September 11, 2024, Robert P. Lenk, a director of Plus Therapeutics, Inc. [PSTV], acquired stock options.
• The options grant the right to buy 3,650 shares of common stock at an exercise price of $1.26.
• The options vest monthly over 12 months from the grant date, or in full at the next annual meeting of stockholders, subject to continued service.
• Following the transaction, Lenk directly owns 3,650 derivative securities.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard insider transaction disclosure. The acquisition of options by a director can be seen as a mildly positive signal, but it's not a major event.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The transaction provides shareholders with information about insider activity, which can influence investor sentiment.

Key Dates

Keywords

stock options, Form 4, director, PSTV, Plus Therapeutics, beneficial ownership